Volume 3, Issue 10 (6-2013)                   NCMBJ 2013, 3(10): 21-26 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Bikhof Torbati M, Shaabanzadeh M, Safari M, Soleymani Ahoee T, Khosravi F. Synthesis and antitumor evaluation of spiro quinoxaline-pyrazoline derivative on K562 cell line. NCMBJ. 2013; 3 (10) :21-26
URL: http://ncmbjpiau.ir/article-1-330-en.html
Department of Biology, Shahr-e-Rey Branch, Islamic Azad University, Tehran, Iran , maryam.bikhof@gmail.com
Abstract:   (18571 Views)

Aim and Background: The quinoxaline and pyrazoline derivatives have variety of biological effects, which made them useful pharmaceutical agents, such as cytotoxicity activities, that will be appropriate in chemotherapy of tumors. In this study, 5'-phenyl-2',4'-dihydrospiro[indeno[1,2-b]quinoxaline-11,3'-pyrazole] compound was synthesized and studied cytotoxic effect on K562 cell line and PBMC by MTT assay. 

Materials and Methods: 5'-Phenyl-2',4'-dihydrospiro[indeno[1,2-b]quinoxaline-11,3'-pyrazole] compound by one pot assay was synthesized and studied anti tumor activity on blood cancer cell line ,K562, and healthy human hole blood activated PBMC by MTT assay. In addition, cytotoxic effects of cisplatin on the same cells were studied.

Results: This compound showed antitumor activity with IC50 of 0.92 and 0.75 µg/ml respectively on K562 cell line and PBMC+PHA. While cisplatin, as a kind of standard drug in chemotherapy, inhibited proliferation of the same cells respectively with IC50, 1.71 and 7.8 µg/ml.

Conclusion: The obtain results showed compound 4 is cytotoxic more than cisplatin on K562 cell line and activated PBMC by PHA.

Full-Text [DOC 36 kb]   (5303 Downloads)    
Type of Study: Research Article | Subject: Cellular and molecular
Received: 2013/05/26 | Published: 2013/06/15

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2021 CC BY-NC 4.0 | New Cellular and Molecular Biotechnology Journal

Designed & Developed by : Yektaweb